Discontinued — last reported Q3 '23
Cboe Global Markets Equity Method Investments decreased by 7.7% to $29.90M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 52.2%, from $62.50M to $29.90M. Over 5 years (FY 2020 to FY 2025), Equity Method Investments shows a downward trend with a -5.4% CAGR.
An increase indicates strategic expansion through partnerships or joint ventures, while a decrease may signal divestments or impairment.
These are investments in entities where the company exercises significant influence but does not have full control. The...
Varies significantly based on corporate strategy; common in healthcare companies that partner with biotech startups or specialized diagnostic firms.
equity_method_investments| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $41.10M | $36.00M | $245.80M | $244.50M | $243.50M | $253.60M | $253.20M | $269.70M | $294.20M | $342.60M | $345.30M | $361.80M | $359.50M | $37.00M | $383.70M | $62.50M | $62.40M | $67.40M | $32.40M | $29.90M |
| QoQ Change | — | -12.4% | +582.8% | -0.5% | -0.4% | +4.1% | -0.2% | +6.5% | +9.1% | +16.5% | +0.8% | +4.8% | -0.6% | -89.7% | +937.0% | -83.7% | -0.2% | +8.0% | -51.9% | -7.7% |
| YoY Change | — | — | — | — | +492.5% | +604.4% | +3.0% | +10.3% | +20.8% | +35.1% | +36.4% | +34.1% | +22.2% | -89.2% | +11.1% | -82.7% | -82.6% | +82.2% | -91.6% | -52.2% |